A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.

已取消 40 由 wangzzzz 发布于 2025/7/15 9:10:06

DOI:10.1182/blood.2024026401
作者：Wenjuan Yu,Ping Li,Lili Zhou,Min Yang,Shiguang Ye,Dan Zhu,Jiaqi Huang,Xin Yao,Yan Zhang,Lanfang Li,Jing Zhao,Kevin Zhu,Jing Li,Chengxiao Zheng,Liping Lan,Hui Wan,Yihong Yao,Huilai Zhang,Daobin Zhou,Ji
文献类型：期刊论文
补充材料：仅需补充材料
文献链接：https://doi.org/10.1182/blood.2024026401
管理员驳回:未在官网发现补充材料

American Society of Hematology (ASH)

Abstract：Prizloncabtagene autoleucel (prizlon-cel), a novel bispecific chimeric antigen receptor (CAR) T-cell, targets and eliminates CD19/CD20 positive tumor cells. This phase 1, open-label study in

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:其它数据库Stabilizing Ru-Based Catalysts against Bromine Poisoning through Ru-O Covalency Regulation for Durable Brominated Volatile Organic Compound Oxidation.